Trump close to deal to allow Medicare coverage of weight loss drugs

The Trump administration is reportedly nearing a deal to enable Medicare coverage for Eli Lilly's Zepbound and Novo Nordisk's Wegovy for weight loss in certain cases, a move that could significantly expand access for seniors. This potential arrangement involves substantial price reductions for the drugs, with Wegovy at $149/month and Zepbound at $299/month via TrumpRX, and may also influence broader private insurer coverage. While a White House spokesperson labeled discussions as 'speculation,' this development, if finalized, would mark a reversal of a prior administration's rejection of higher-cost GLP-1 obesity coverage and could substantially increase market penetration for these pharmaceutical companies.

Analysis

The Trump administration is reportedly close to a deal enabling Medicare coverage for Eli Lilly's Zepbound and Novo Nordisk's Wegovy for weight loss in specific cases. This potential agreement would significantly expand access for seniors and drastically reduce estimated coverage costs, with Wegovy priced at $149/month and Zepbound at $299/month via TrumpRX. Such a move could also influence broader coverage decisions by private insurers, amplifying market penetration for these GLP-1 drugs.

The proposed deal represents a substantial pricing concession from drugmakers, aiming to lower costs for Americans, a recurring theme for the administration. This initiative contrasts sharply with the prior administration's rejection of a $40 billion, 10-year proposal for GLP-1 obesity coverage. While a White House spokesman labels discussions as "speculation," the reported terms suggest a strategic shift in drug pricing and accessibility.

The strongly positive sentiment (0.7 overall, 0.8 for LLY and NVO) reflects the potential for increased sales volumes for both Eli Lilly and Novo Nordisk, despite the lower per-unit pricing. Medicare already covers GLP-1s for related conditions, meaning a significant portion of the target demographic is already familiar with the drug class. This expansion into obesity treatment, if finalized, would unlock a substantial new revenue stream and solidify market leadership for these companies.

Key Decisions for Investors

• Monitor official announcements regarding the Medicare deal's finalization, as confirmation would significantly expand market access for Eli Lilly and Novo Nordisk's GLP-1s.
• Assess the long-term revenue implications for LLY and NVO, balancing lower per-unit pricing with the potential for substantially increased sales volumes from Medicare and potentially private insurer coverage.
• Evaluate the precedent this deal sets for future drug pricing negotiations and government-backed coverage expansions within the pharmaceutical sector.
• Observe private insurer responses to this potential Medicare coverage, as their policies often align with government decisions, further impacting market penetration for weight loss drugs.